Labcorp buys BioReference for up to $872 million
Alpha Vantage · Benzinga · · AI-summarised by FinFlash
OPKO Health shares surged after announcing a deal to sell its BioReference Health diagnostics businesses to Labcorp Holdings for up to $872 million. This strategic move allows OPKO Health to concentrate on its core biopharmaceutical operations, while Labcorp expands its diagnostic testing services, including the valuable 4Kscore Test. The transaction is pending regulatory approvals.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.